Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials.

Cureus·2025

Same author

Histopathological Subtypes of Cutaneous Melanoma: Prognostic and Molecular Implications.

Cureus·2025

Same author

Cost-Effectiveness of a Solo Anesthesiologist During Transcatheter Aortic Valve Replacement in Patients With Severe Comorbidities.

Cureus·2025

Same author

Epigenetic Dysregulation in Neurodegenerative Disease: Implications for Neuropathology and Therapy.

Cureus·2025

Same author

Congenital and Neonatal Skin Disorders: Histopathological Diagnosis and Syndromic Associations.

Cureus·2025

Same author

Neuromodulatory Signaling in Chronic Pain Patients: A Narrative Review.

Cells·2025

Search research articles

Related Experiment Video

Updated: Jun 24, 2025

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

Red Wine as an Aromatase Inhibitor: A Narrative Review.

Joseph Pergolizzi¹, Jo Ann K LeQuang², Morgan Wagner³

¹Pain Management, NEMA Research, Inc., Naples, USA.

|June 3, 2024

Summary

Red wine may possess aromatase-inhibiting properties, potentially aiding in breast cancer chemoprevention by reducing estrogen production. Further research is needed to confirm its efficacy and mechanisms, especially compared to non-alcoholic grape extracts.

Keywords:

aromatase inhibitor therapy breast cancer breast cancer care postmenopausal breast cancer red wine

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Related Experiment Videos

Last Updated: Jun 24, 2025

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Area of Science:

Oncology
Pharmacology
Nutraceuticals

Background:

Estrogen-dependent breast cancer growth is influenced by local estrogen production via aromatase.
Aromatase inhibitors are used to treat breast cancer in postmenopausal women by blocking estrogen synthesis.
Red wine contains compounds like polyphenols, tannins, and resveratrol, which may inhibit aromatase activity.

Purpose of the Study:

To explore the potential of red wine as a source of aromatase inhibitors for breast cancer chemoprevention.
To investigate the role of specific red wine constituents in blocking endogenous estrogen production.

Main Methods:

Review of existing literature on aromatase inhibition and the chemical composition of red wine.
Analysis of animal studies investigating the in vivo effects of red wine components on aromatase.
Consideration of challenges in designing clinical trials for variable natural products like red wine.

Main Results:

Red wine, unlike white wine, has shown potential aromatase-inhibiting properties in preliminary studies.
Polyphenols, tannins, and resveratrol are implicated as active constituents, possibly acting synergistically.
Similar benefits have been observed with non-alcoholic grape seed extract, suggesting compound-specific effects.

Conclusions:

While red wine shows promise for chemoprevention, current evidence is insufficient to advocate for its use as an aromatase inhibitor.
Further clinical investigation is warranted to elucidate mechanisms and confirm efficacy, considering the variability of red wine.
The role of aromatase inhibition in premenopausal breast cancer remains unclear.